JPRN-UMIN000004991已完成2 期
Phase II study of panitumumab with FOLFOX or FOLFIRI as 1st line treatment in patients with metastatic colorectal cancer in Japan - Phase II study of panitumumab with FOLFOX or FOLFIRI as 1st line treatment for metastatic CRC in Japan (PaFF-J)
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 165
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Prior severe drug allergy 2) Synchronous and/or metachronous multiple cancers 3) Severe bowel stenosis by the primary tumor (ex. after colostomy) 4) Prior adjuvant chemotherapy with oxaliplatin containing regimen 5) Surgical procedure within 28 days prior to enrollment (ex. venous reservoirs implant, colostomy) 6) Severe comorbidity: - severe pulmonary dysfunction - Uncontrolled DM - Uncontrolled HT - severe cardiovascular disease - Cirrhosis and liver failure - Renal failure 7) Sensory neuropathy 8) Severe diarrhea 9) Active infection 10) Symptomatic pleural effusion or ascites 11) Contraindications to 5-FU, l-LV, panitumumab, L-OHP or CPT-11 12) Concerning pregnancy 13) The investigator considers not suitable for the study
研究者
相似试验
招募中
2 期
FFCD 1605- OPTIPRIME: A phase II study evaluating FOLFOX + panitumumab according to a ‘stop-and-go’ strategy with a reintroduction loop after progression on fluoropyrimidine as maintenance treatment, as the first line in patients with metastatic colorectal adenocarcinoma without a RAS mutation2024-518740-20-00Fondation Franc.Cancerologie Digestive118
进行中（未招募）
不适用
PHASE II TRIAL OF FOLFOXIRI PLUS PANITUMUMAB AS FIRST-LINE TREATMENT FOR KRAS AND BRAF WILD-TYPE METASTATIC COLORECTAL CANCER - TRIPEUCTR2009-014556-29-ITG.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST
进行中（未招募）
1 期
Clinical study to evaluate, in patients selected with the new technology, the efficacy and safety of the combination of Folfiri + Panitumumab in patients with stage IV colorectal cancer refractory to irinotecan without any mutation on KRAS, PIK3Ca, BRAF and NRAS genes detected with highly sensitive techniques.EUCTR2012-001955-38-ESGrupo de Tratamiento de los Tumores Digestivos (TTD)50
进行中（未招募）
1 期
Analysis of 2nd line panitumumab + FOLFIRI efficacy in wild type RAS converted subjects from initially mutated RAS subjects with metastatic colorectal cancer treated in 1st line with standard FOLFOX + bevacizumab treatment.Wild-type RAS metastatic colorectal cancer (mCRC)MedDRA version: 20.0Level: PTClassification code 10052358Term: Colorectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-003242-25-ESASOCIACION GITuD40
进行中（未招募）
1 期
A Phase 2 Study of Panitumumab Plus Irinotecan Followed by Panitumumab PlusAMG 479 in Subjects With Metastatic Colorectal Carcinoma Expressing Wild Type KRAS and Refractory to Oxaliplatin- or Irinotecan- and Oxaliplatin-containing Regimens to Evaluate Mechanisms of Acquired Resistance to PanitumumabMetastatic colorectal cancerMedDRA version: 9.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerEUCTR2008-004752-77-FRAmgen Inc76